Article Information
History
- July 10, 2024.
Article Versions
- Version 1 (June 30, 2023 - 13:31).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Merle-Marie Pittelkow1,2,*,
- Maximilian Linde1,3,
- Ymkje Anna de Vries4,
- Lars G. Hemkens5,6,7,8,
- Andreas M. Schmitt6,9,
- Rob R. Meijer1 and
- Don van Ravenzwaaij1
- 1Faculty of Behavioural and Social Sciences, University of Groningen, Groningen, the Netherlands
- 2QUEST Center for Responsible Research, Berlin Institute of Health at Charité, Berlin, Germany
- 3GESIS - Leibniz Institute for the Social Sciences, Cologne, Germany
- 4Department of Child and Adolescent Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
- 5Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland
- 6Department of Clinical Research, University of Basel and University Hospital Basel, Basel, Switzerland
- 7Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California, USA
- 8Meta-Research Innovation Center Berlin (METRIC-B), Berlin Institute of Health, Berlin, Germany
- 9Department of Medical Oncology, University Hospital Basel, Basel, Switzerland
- ↵*Correspondence to: merle-marie.pittelkow{at}bih-charite.de, Anna-Louisa-Karsch Straße 2, 10178 Berlin, Germany
Posted July 10, 2024.
Strength of Statistical Evidence for the Efficacy of Cancer Drugs: A Bayesian Re-Analysis of Randomized Trials Supporting FDA Approval
